| Name | Title | Contact Details |
|---|---|---|
Arturo Morales |
Chief Technology Officer | Profile |
Nightstar is a private biopharmaceutical company focused on the development of therapies for retinal dystrophies. The Company’s lead programme is a retinal gene therapy for choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Gene therapy has the potential to be an effective treatment for choroideremia and a range of other retinal dystrophies. The Company’s lead investors are Syncona LLP and NEA Inc. Syncona is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to impact significantly the healthcare market of the future. NEA is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies.
Andau Medical is a Canadian Medical Device and Dental Device company focused on providing the market with quality technologies that improve patient outcomes and enhance the clinical experience in delivering exceptional patient care.
Our mission at Kelyniam is to apply 3D printing and rapid prototyping technology to create innovative medical products that improve the lives of physicians and their patients.
GeNOsys (generated nitric oxide systems) Inc. is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas
Westerner Park is a Red Deer, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.